Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Luger

Showing results (191-200 of 311) with videos related to

Pageof 32
Sort By:
The Lancet. Haematology|December 5, 2024
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemiaIbrahim Aldoss, Gail J Roboz, Renato Bassan, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 14, 2015
Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based SurveyEun-Ju Lee, B Douglas Smith, Jessica W Merrey, et al.
Transplantation Proceedings|March 20, 1999
Influence of an historically positive crossmatch on cadaveric renal transplantationC F Bryan, C F Shield, B A Warady, et al.
Leukemia Research|July 3, 2014
Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patientsJustin M Watts, Xin Victoria Wang, Mark R Litzow, et al.
Clinical Lymphoma|July 3, 2003
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibodyDonald E Tsai, Ivan Maillard, Stephen J Schuster, et al.
Cancer Biology & Therapy|February 18, 2010
Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48 hoursAnthony R Mato, Selina M Luger, Daniel F Heitjan, et al.
Science Signaling|February 10, 2026
Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemiaJaewoong Lee, Ruifeng Sun, Kohei Kume, et al.
Blood Advances|October 1, 2021
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trialsChezi Ganzel, Ju-Whei Lee, Hugo F Fernandez, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 21, 2023
One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplantLindsey Chippendale, Craig W Freyer, Alison Carulli, et al.
Cancer Research|December 25, 2002
Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2Mary Ann C Sabino, Joseph R Ghilardi, Joost L M Jongen, et al.
Pageof 32

Showing results (191-200 of 311) with videos related to

Sort By:
Pageof 32
The Lancet. Haematology|December 5, 2024
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemiaIbrahim Aldoss, Gail J Roboz, Renato Bassan, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 14, 2015
Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based SurveyEun-Ju Lee, B Douglas Smith, Jessica W Merrey, et al.
Transplantation Proceedings|March 20, 1999
Influence of an historically positive crossmatch on cadaveric renal transplantationC F Bryan, C F Shield, B A Warady, et al.
Leukemia Research|July 3, 2014
Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patientsJustin M Watts, Xin Victoria Wang, Mark R Litzow, et al.
Clinical Lymphoma|July 3, 2003
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibodyDonald E Tsai, Ivan Maillard, Stephen J Schuster, et al.
Cancer Biology & Therapy|February 18, 2010
Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48 hoursAnthony R Mato, Selina M Luger, Daniel F Heitjan, et al.
Science Signaling|February 10, 2026
Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemiaJaewoong Lee, Ruifeng Sun, Kohei Kume, et al.
Blood Advances|October 1, 2021
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trialsChezi Ganzel, Ju-Whei Lee, Hugo F Fernandez, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 21, 2023
One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplantLindsey Chippendale, Craig W Freyer, Alison Carulli, et al.
Cancer Research|December 25, 2002
Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2Mary Ann C Sabino, Joseph R Ghilardi, Joost L M Jongen, et al.
Pageof 32